Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. With the latest financial year loss of US$127m and a trailing-twelve-month loss of US$165m, the US$1.1b market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which UroGen Pharma will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts' expectations for the company. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Consensus from 8 of the American Biotechs analysts is that UroGen Pharma is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$115m in 2027. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each yea
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma says permanent J Code for ZUSDURI now in effect [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyGlobeNewswire
- Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
URGN
Earnings
- 11/6/25 - Beat
URGN
Analyst Actions
- 10/27/25 - HC Wainwright
URGN
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- URGN's page on the SEC website